Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PF-06809247
- Development stage
- Phase 1
- Lead developer
- Pfizer
- Modality
- Alpha Emitters → Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta Emitters → Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
PF-06809247 is a potent and selective irreversible inhibitor of monoacylglycerol lipase (MAGL), a serine hydrolase that plays a key role in regulating endocannabinoid signaling in the brain. Developed by Pfizer, this compound has been radiolabeled ([11C]PF-06809247) for use as a positron emission tomography (PET) ligand to enable noninvasive and quantitative imaging of MAGL expression and occupancy in the brain across species, including humans. The drug exhibits high specificity for MAGL, making it valuable for both preclinical research and clinical studies investigating neurological disorders associated with endocannabinoid signaling dysregulation. Its primary application is as an imaging agent rather than as a therapeutic[1][3][6].
- Other names
- [11C]PF-06809247
02
Targets
MGLL (Monoacylglycerol lipase)
Beyond the preview
Go deeper on PF-06809247.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PF-06809247.